Oxyntomodulin vs UBT251
Head-to-head comparison of Oxyntomodulin (Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide) and UBT251 (UBT251, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Oxyntomodulin | UBT251 |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide | UBT251, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist |
| Molecular Weight | ~4,200 Da | N/A |
| Half-Life | 12-15 minutes | Approximately 1 week |
| Amino Acids | 37 | N/A |
| Typical Dose | Research doses vary; commonly 100-300 mcg in small human studies | Investigational; no established human dose |
| Route | Subcutaneous/IV | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 80 | 8 |
| Research Status | Clinical | Pre-clinical |
Oxyntomodulin Benefits
- ✓reduces appetite
- ✓increases satiety
- ✓supports weight loss
- ✓improves postprandial metabolic signaling
UBT251 Benefits
- ✓weight reduction
- ✓improved satiety
- ✓enhanced energy expenditure
- ✓better insulin sensitivity
Oxyntomodulin Dosing
Research-only dosing|Subcutaneous or IV administration in trials|Pair with calorie restriction and monitoring
UBT251 Dosing
once-weekly subcutaneous injection|dose escalation in studies|maintenance after tolerability assessment
Oxyntomodulin Side Effects
- ⚠nausea
- ⚠GI discomfort
- ⚠decreased appetite beyond target
UBT251 Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠fatigue
Research Overview
Oxyntomodulin
Human studies showed acute reductions in food intake and modest weight loss, helping establish the GLP-1 and glucagon co-agonism concept. It remains a foundational peptide for obesity and satiety research.
UBT251
Published work supports strong anti-obesity activity in preclinical models, with translation into human studies still emerging. The compound remains investigational and is best characterized as an early multi-agonist program.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.